MA-VERISTAT
7.4.2021 14:02:07 CEST | Business Wire | Press release
Veristat , a scientific-minded, global clinical research organization (CRO), announced today that it transferred its majority ownership from Variance Development Partners to WindRose Health Investors (WindRose). WindRose invests exclusively in healthcare companies and has extensive experience across the healthcare services landscape, including outsourced biopharmaceutical services like Veristat’s.
“As a founder of Veristat, I believe that Veristat has attained the ideal investment partner who understands our philosophy, our values, and the impact we make in clinical research,” stated John P. Balser, Ph.D., President, Co-Founder, and Chief Statistical Officer of Veristat. “WindRose has a track record of successful collaboration, understands the critical nature of the scientific and therapeutic expertise we offer and will bring significant knowledge and a network of advisors to assist us as we continue to evolve.”
WindRose will support Veristat’s continued expansion to meet the needs of its growing client base around the world. This partnership will significantly benefit Veristat by complementing the leadership team with a group of diverse and knowledgeable healthcare advisors who share the same vision, culture, and focus on scientific excellence in clinical research.
“We are excited to enter into this relationship with Veristat,” said CJ Burnes, Partner with WindRose. “The Company’s clinical impact and scientific approach to partnering with companies advancing life-enhancing therapies is impressive. Their market position, stellar reputation, and leadership within biostatistics and ability to design and conduct complex clinical trials is unlike any other we have seen. In partnership with the management team and the founders, WindRose plans to contribute substantial resources to support the execution of Veristat’s strategy.”
“I am confident that our partnership with WindRose will allow Veristat’s continued focus on our core mission of helping sponsors solve the challenges that arise when developing ground-breaking products that improve and save lives through our differentiated approach to designing and executing clinical trials, clinical programs, regulatory submissions, and pharmacovigilance,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “WindRose will provide us the capital and a deep network of relationships and expertise in the biotech and pharmaceutical industry as we strategically grow our company.”
Edgemont Partners acted as financial advisor to Veristat. Nutter McClennen & Fish LLP acted as legal advisor to Veristat, and McDermott Will & Emery LLP acted as legal advisor to WindRose.
About WindRose
WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. WindRose manages over $1.2 billion in investments and is currently investing out of its fifth fund. WindRose is based in New York City and invests in companies throughout the United States.
For more information, email WindRose at info@windrose.com .
About Veristat
Veristat , a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perpetuals Reports $4.5 Billion in UpsideOnly Volume and Signs Exchange Agreement With Datavault AI for Tokenized Commodities2.6.2026 14:00:00 CEST | Press release
UpsideOnly draws more than 30,000 active users from 185 countries in its first two weeksPerpetuals signs exchange agreement with Datavault AI, bringing tokenized gold, copper, geothermal energy, and critical minerals to 24/7 regulated global trading Perpetuals.com Ltd (Nasdaq: PDC) today reported strong early results for its breakout UpsideOnly trading and market prediction platform and announced an agreement with Datavault AI Inc. (Nasdaq: DVLT) to list tokenized real-world commodity assets on the Perpetuals platform. In its first two weeks, traders flocked to the UpsideOnly platform, attracting more than 30,000 active users, generating $4.5 billion in cumulative platform volume across 186,000 fills and 25 instruments. Reflecting the widespread demand for a risk-free product, users came from 185 different countries. Surprisingly, gold was the top instrument with $1.4 billion in volume, outpacing bitcoin at $1.2 billion with precious metals accounting for roughly 35 percent of total pl
Phenom Positioned as Strategic Leader in Fosway 9-Grid™ for Talent Acquisition Sixth Consecutive Year2.6.2026 14:00:00 CEST | Press release
Recognition reflects sustained customer outcomes as enterprises move from AI experiments to production deployments Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602897994/en/ Phenom has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. The execution gap is well documented. Fosway’s recent AI Market
How Fit Analytics Innovation Reclaimed its Independence to Build the Future of AI Commerce2.6.2026 13:47:00 CEST | Press release
With today’s launch of the AI Shopping Assistant, Fit Analytics Innovation moves beyond the AI-hype-cycle to deliver the conversational guidance modern apparel shoppers crave. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602315868/en/ AI Shopping Assistant - Fit Analytics Innovation Two years ago, Fit Analytics Innovation did the unthinkable: they bought themselves back. Following a high-profile acquisition by Snap Inc., the management team recovered the award-winning Fit Finder and secured sixteen years of expertise and data insights. That bet on independence has culminated in the launch of the AI Shopping Assistant, the latest module available as part of their expanded product suite. Delivering Performance Over P.R. Unlike "overnight" AI startups rushing for market share, Fit Analytics has utilized its independence to prioritize depth over hype. The resulting AI Shopping Assistant is a native evolution of the company’
Kinaxis Introduces Forward Deployed Engineering to Help Enterprises Turn Decisions into Outcomes2.6.2026 13:01:00 CEST | Press release
New engineering-led engagement model helps organizations co-build AI-native operational solutions using the Maestro platform Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today introduced Forward Deployed Engineering (FDE), a new engagement model designed to help enterprises operationalize AI and translate decisions into measurable business outcomes. FDE reflects the broader Kinaxis vision for operational orchestration, an approach that coordinates signals, decisions, actions and learnings across the business fast enough to change outcomes. The opening keynote at Kinexions, the company’s global customer conference, delivered by CEO Razat Gaurav will be livestreamed globally on June 2 @ 11:30 am EST via LinkedIn Live. This approach combines a unified data foundation with semantic intelligence that understands the relationships, dependencies, and trade-offs that shape enterprise operations. Together, these capabilities help organizations move beyond
NIQ Launches Product Intelligence to Power AI-Driven Commerce2.6.2026 13:00:00 CEST | Press release
New solution structures and enriches fragmented product data to help brands and retailers fuel AI discovery, recommendations, and agentic commerce NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Product Intelligence, a new solution designed to help retailers and brands transform fragmented product data into structured, interoperable intelligence that fuels AI-driven commerce. As AI increasingly shapes how consumers discover, evaluate, and purchase products, the quality and completeness of product data have become a defining competitive advantage. In AI-mediated commerce environments, products that lack structured, enriched, and machine-readable data risk becoming invisible to recommendation engines, AI assistants, and autonomous purchasing agents. NIQ Product Intelligence addresses this challenge by creating a unified product intelligence layer that standardizes attributes, resolves product identity across systems, and enriches product data at scale, enabling AI systems to bett
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom